Rowe R Grant, Guo Dongjing, Lee Michelle, Margossian Steven, London Wendy B, Lehmann Leslie
Stem Cell Transplantation Program, Dana-Farber Boston Children's Cancer and Blood Disorders Center, Dana-Farber Cancer Institute, Boston, Massachusetts; Boston Children's Hospital, Boston, Massachusetts.
Boston Children's Hospital, Boston, Massachusetts.
Biol Blood Marrow Transplant. 2016 Jul;22(7):1275-1283. doi: 10.1016/j.bbmt.2016.04.004. Epub 2016 May 8.
Cytomegalovirus (CMV) infection is a significant source of morbidity and mortality in allogeneic stem cell transplantation (SCT). We identified a cohort of 91 pediatric SCT patients at risk (defined as either donor and/or recipient seropositivity) for CMV infection at our institution. We retrospectively categorized at-risk SCT recipients as those who (1) were at risk of CMV infection in the post-SCT period, (2) had documented CMV infection before SCT, (3) experienced recurrence of post-SCT CMV viremia, or (4) experienced late post-SCT CMV viremia; categories were not mutually exclusive. We analyzed the impact of SCT-related factors on incidence of CMV infection and outcome, and we described the outcome of each of these cohorts. In univariate analysis, recipient CMV seropositivity, use of umbilical cord blood graft, and acute graft-versus-host disease (GVHD) predicted post-SCT CMV viremia, and the effects of acute GVHD (odds ratio, 4.018; 95% confidence interval, 1.032 to 15.643) and CMV seropositivity (odds ratio, 16.525; 95% confidence interval, 2.041 to 133.803) were confirmed in multivariate analysis. Patients with recurrence of post-SCT CMV viremia had a 50% all-cause mortality rate, compared with 12% in all 91 patients. Patients with pre-SCT CMV infection had a high incidence of post-SCT CMV infection but could successfully undergo SCT with antiviral prophylaxis and pre-emptive CMV treatment. All patients with late CMV infection had prior GVHD. Theses findings identify risk factors for post-SCT CMV infection and provide novel descriptions of childhood SCT recipients with pre-SCT, recurrent, and late CMV infection, which may contribute to risk stratification strategies for CMV at-risk patients in pediatric allogeneic SCT.
巨细胞病毒(CMV)感染是异基因造血干细胞移植(SCT)中发病和死亡的重要原因。我们在本机构确定了一组91名有CMV感染风险(定义为供体和/或受体血清学阳性)的儿科SCT患者。我们回顾性地将有风险的SCT受者分类为:(1)在SCT后时期有CMV感染风险的患者;(2)在SCT前有记录的CMV感染患者;(3)经历SCT后CMV病毒血症复发的患者;或(4)经历SCT后晚期CMV病毒血症的患者;这些类别并非相互排斥。我们分析了SCT相关因素对CMV感染发生率和结局的影响,并描述了每个队列的结局。在单因素分析中,受体CMV血清学阳性、脐带血移植物的使用以及急性移植物抗宿主病(GVHD)可预测SCT后CMV病毒血症,多因素分析证实了急性GVHD(比值比,4.018;95%置信区间,1.032至15.643)和CMV血清学阳性(比值比,16.525;95%置信区间,2.041至133.803)的影响。SCT后CMV病毒血症复发的患者全因死亡率为50%,而所有91名患者的全因死亡率为12%。SCT前有CMV感染的患者SCT后CMV感染发生率较高,但通过抗病毒预防和抢先性CMV治疗可成功进行SCT。所有晚期CMV感染患者均有既往GVHD。这些发现确定了SCT后CMV感染的危险因素,并提供了对SCT前、复发和晚期CMV感染的儿童SCT受者的新描述,这可能有助于儿科异基因SCT中CMV风险患者的风险分层策略。